Tuesday, 21 Jan 2020

You are here

Oral Prednisolone and NSAIDs Equipotent in Acute Gout

An emergency department based study evaluated the efficacy and safety of oral prednisolone versus indomethacin in 416 patients with acute gout in a multicenter, double-blind, randomized trial.

There were 376 patients who completed the 14-day study, and the primary outcome was pain by 100 mm visual analogue scale.

Equivalent and clinically significant within-group reductions in mean pain score were observed with indomethacin and prednisolone acutely in the emergency department (approximately 10 mm improvement at rest and 20 mm improvement with activity) and later (from days 1 to 14) patients improved approximately 25 mm [rest] and 45 mm [activity].

No major adverse events occurred during the study. In the emergency department, indomethacin group had more minor adverse events than those in the prednisolone group (19% vs. 6%; P < 0.001). 

Oral prednisolone and indomethacin had similar analgesic effectiveness among patients with acute gout. Prednisolone is an effective and safe first-line option for treatment of acute gout.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Diabetics using SGLT2 Inhibitors have a lower Gout Risk

Researchers from the Brigham and Women's Hospital have reported that adults with type 2 diabetes who were treated with SGLT2 inhibitors had a lower risk of gout compared to GLP1 agonist, suggesting that sodium–glucose cotransporter-2 inhibitors may reduce the risk for gout with type 2 diabetes mellitus (T2DM).

A Role for SGLT2 Inhibition in Gout?

The antidiabetic medication canagliflozin (Invokana) lowered serum urate and reduced the risk of gout flare in a post-hoc analysis of data from two large clinical trials.

Predicting Inpatient Gout Flares

Analysis of New Zealand hospitalized patients revals nine predictors of inpatient flare for people with comorbid gout.

This retrospective cohort study of hospitalised patients with comorbid gout included 625 hospitalised patients, 87 experienced inpatient gout flare.

There were 9 predictors of an inpatient gout flare:

Pegradicase+ImmTOR SEL-212 Shows Promising Results In Active Gout

Therapies targeting sUA accumulation or improving its excretion are widely used for treatment of symptoms and prevention of progression of gout for decades. Despite our best effort, there is still a significant amount of patients who remain symptomatic and/or experiences progressive joint damage and disability. Regardless of the cause, either its lack of compliance or poor tolerability, more effective treatments are needed.

PANLAR Ultrasound Study Group: Recommendations On Imaging Modalities In Gout

Gout is a systemic inflammatory disease with high potential for joint damage due to erosive changes and MSU deposits resulting in disability and chronic pain. Prompt diagnosis and effective treatment are key to better long term outcomes and decreased disability.